RSS
BIIB icon

Rosenblum Silverman Sutton’s Biogen BIIB Stock Holding History

Rosenblum Silverman Sutton’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,827
Closed -$1.55M – 62
2015
Q2 		$1.55M Buy
+3,827
New +$1.54M 0.62% 50
2014
Q4 		$614K Hold
1,810
– – 0.26% 56
2014
Q3 		$599K Hold
1,810
– – 0.27% 57
2014
Q2 		$571K Sell
1,810
-100
-5% -$30.1K 0.27% 56
2014
Q1 		$584K Buy
1,910
+305
+19% +$96.8K 0.28% 60
2013
Q4 		$449K Buy
1,605
+60
+4% +$15.5K 0.21% 62
2013
Q3 		$372K Buy
+1,545
New +$346K 0.2% 59

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Rosenblum Silverman Sutton's BIIB Position: Q3 2015 in Review

Rosenblum Silverman Sutton sold out of Biogen (BIIB) in Q3 2015, closing a stake of 3,827 shares — an estimated $1.55M sold.

Rosenblum Silverman Sutton first reported a position in BIIB in Q3 2013 and held it in 7 quarters. The position peaked at $1.55M in Q2 2015. 924 funds tracked by Wall St. Rank hold BIIB as of Q3 2015.

  • Rosenblum Silverman Sutton reported no remaining Biogen position as of Q3 2015 after selling out during the quarter.
  • Rosenblum Silverman Sutton sold 3,827 Biogen shares in Q3 2015, an estimated $1.55M.
  • Rosenblum Silverman Sutton first reported a position in Biogen in Q3 2013 and held it in 7 quarters.
  • Rosenblum Silverman Sutton's Biogen position peaked at $1.55M in Q2 2015.
  • 924 funds tracked by Wall St. Rank held Biogen as of Q3 2015.

Based on Rosenblum Silverman Sutton's 13F filing for Q3 2015, filed 16 Nov 2015.